Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of AE 37 in patients with prostate cancer

Trial Profile

Phase II trial of AE 37 in patients with prostate cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AE 37 (Primary)
  • Indications Prostate cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Shenzhen BioScien Pharmaceuticals
  • Most Recent Events

    • 16 Jan 2020 According to a Generex Biotechnology Corporation media release, as per the licensing agreement between Generex and Shenzhen, Shenzhen is planning a global trial in China and in Europe using one of Generexs clinical research sites that have previous experience conducting clinical trials with AE37.The company looks forward to seeing further progress with the prostate cancer clinical trial in 2020.
    • 16 Jan 2020 According to a Generex Biotechnology Corporation media release, the company has a licensing and development agreement with Shenzhen Bioscien, or the use of AE37 in the treatment of prostate cancer in China.Companys partners at Shenzhen are working with the Chinese regulatory authorities to obtain approval for conducting trials in China, which includes fulfilling manufacturing and pre-clinical requirements.
    • 05 Oct 2018 According to a Generex Biotechnology Corporation media release, Shenzhen plans to initiate this trial in Europe in 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top